Reuters logo
BRIEF-Nordic Nanovector, Legochem Biosciences to jointly develop ADCs targeting leukaemias
October 10, 2016 / 5:10 AM / a year ago

BRIEF-Nordic Nanovector, Legochem Biosciences to jointly develop ADCs targeting leukaemias

Oct 10 (Reuters) - Nordic Nanovector ASA :

* Says has entered into cooperation with Legochem Biosciences, South Korea-based biopharmaceutical company, to develop novel antibody-drug conjugates (ADCs) targeting leukaemias

* Says collaboration supports co’s strategy to expand its pipeline of targeted therapies to include CD37-targeting antibody products conjugated to anti-cancer compounds that are not radionuclides Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below